Eversept Partners, LP Krystal Biotech, Inc. Transaction History

Eversept Partners, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $6.72 Million - $11.2 Million	-62,241 Reduced 77.03%	18,557 $3.3 Million
Q4 2023 Feb 14, 2024	SELL	$96.0 - $128.29 $2.69 Million - $3.59 Million	-27,973 Reduced 25.72%	80,798 $10 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $250,224 - $300,287	2,306 Added 2.17%	108,771 $12.6 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $8.36 Million - $13.9 Million	106,465 New	106,465 $12.5 Million

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.